Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cell lines have been permanently established from BALB/c3T3 cells that constitutively express either the murine
p53
, the human
IGF-1
gene, or both (Gai et al., 1988). The derivative cell lines grow well in platelet-poor plasma or in serum-free medium supplemented with the appropriate growth factors, while BALB/c3T3 cells do not grow in platelet-poor plasma, nor do they grow in serum-free medium unless supplemented with both platelet-derived growth factor and insulin (or
IGF-1
). In BALB/c3T3 cells, steady-state levels of c-myc mRNA decrease promptly and sharply once the cells are transferred to platelet-poor plasma. In the derivative cell lines, constitutively expressing
p53
,
IGF-1
, or both, c-myc mRNA levels remain elevated and actually increase when the cells are transferred to platelet-poor plasma. In serum-free medium, the c-myc mRNA levels decreased in BALB/c3T3 cells, as well as in the derivative cell lines. However, in the latter cell lines, but not in BALB/c3T3, the addition of platelet-poor plasma or insulin again increased the expression of c-myc. The increase in c-myc mRNA levels could be partially explained by an increase in transcription. These results indicate that in certain cell lines the expression of c-myc mRNA can be induced by insulin or platelet-poor plasma.
...
PMID:Regulation of c-myc mRNA levels by insulin or platelet-poor plasma. 269 56
Two constructs (co-transfected with selectable markers) were used to establish cell lines from BALB/c3T3 cells: a
p53
mini-gene under the control of an LTR promoter and a synthetic
IGF-1
coding sequence driven by the SV40 early promoter. BALB/c3T3 cells do not grow in plasma or in 1% serum or in soft agar and in defined media require both platelet-derived growth factor (PDGF) and insulin (or
IGF-1
). Cells carrying only the LTR/
p53
mini-gene grew well in plasma (but not in 1% serum), in soft agar and in serum-free medium containing only insulin. Cells carrying only the SV40/
IGF-1
gene grew (but not too vigorously) in soft agar and grew well in serum-free medium containing PDGF but no insulin. Cells carrying both constructs grew very well in plasma, in soft agar and in serum-free medium without PDGF nor insulin. The results indicate that the requirements for growth of BALB/c3T3 cells can be reduced to two genes:
IGF-1
and a gene replacing PDGF (
p53
in our case). An unexpected, but interesting observation was that cells carrying the LTR/
p53
gene grew slower in 10% serum than in plasma.
...
PMID:Abrogation of the requirements for added growth factors in 3T3 cells constitutively expressing the p53 and IGF-1 genes. 306 89
Transcriptional activation of target genes represents an important component of the tumour-suppressor function of
p53
and provides a functional link between
p53
and various growth-regulatory processes, including cell cycle progression (p21/WAF1), DNA repair (GADD45) and apoptosis (bax). Here we use a differential cloning approach to identify the gene encoding insulin-like growth factor binding protein 3 (IGF-BP3) as a novel
p53
-regulated target gene. Induction of IGF-BP3 gene expression by wild-type but not mutant p53 is associated with enhanced secretion of an active form of IGF-BP3 capable of inhibiting mitogenic signalling by the insulin-like growth factor
IGF-1
. Our results indicate that IGF-BP3 may link
p53
to potential novel autocrine/paracrine signalling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation and survival.
...
PMID:Induction of the growth inhibitor IGF-binding protein 3 by p53. 756 79
Although a minor cause of cancer mortality, thyroid tumors represent a simple and hence powerful experimental model for studying the cell and molecular biology of tumorigenesis in human epithelial cells. This review uses current knowledge of the physiology of growth control in the thyroid as a framework for discussing the somatic genetic abnormalities responsible for follicular cell tumors. Specific emphasis is placed on the predictable involvement of the G-protein oncogene gsp, the key early role of the ras oncogene family, and the apparent rarity of mutations in the
p53
tumor-suppressor gene. Potential contributions of the thyroid model to our understanding of interactions between growth regulatory genes are discussed, particularly the relationships between ras and
IGF-1
and between
p53
and TGF-beta. Throughout, thyroid tumor data are related to that from other tumor types and interpreted in the context of a general model of cell proliferation.
...
PMID:Molecular basis of epithelial tumorigenesis: the thyroid model. 841 49
Human papillomavirus-16 E6 and E7 inactivate the tumor suppressors
p53
and pRB, respectively, and cooperate during malignant transformation, but the downstream molecular events remain incompletely understood. Using fibroblast cell lines derived from mice with a homozygous disruption of the insulin-like growth factor-1 receptor (IGF-1R) gene (R- cells) and their wild-type (WT) littermates, we have stably transfected plasmids encoding E6 and E7 proteins and examined their transforming potential in these cells. Consistent with previous studies using NIH3T3 cells, pooled cultures of E7-transfected WT cells readily formed colonies after suspension in soft agar. In contrast, R- cells were not transformed by E7. E6 had little transforming activity in WT (WT/E6) or R- (R-/E6) cells. However, transfection of R- cells with E6 plus E7 resulted in extensive colony formation. Because IGF-1R and E6 appear to be functionally equivalent in this transformation assay and both have been implicated in antiapoptotic responses, we investigated the apoptotic responses of the cells after exposure to the potent protein kinase C inhibitor, staurosporine. Compared to WT cells, R- cells were relatively resistant to staurosporine-induced apoptosis, but susceptibility to staurosporine was decreased in both WT/E6 and R-/E6 cells relative to WT and R- cells transfected with mock vector, respectively. In fibroblast cells from
p53
gene knockout mice, transfection with E6 also conferred relative resistance to staurosporine-induced apoptosis. Our data suggest that transformation by E7 requires the participation of the IGF-1R and that E6 may assist E7 in transforming R- cells by functionally substituting for the IGF-1R. Because IGF-1R activated by its ligands (
IGF-1
and IGF-2) protects cells from apoptosis, the role of the IGF-1R and E6 in transformation by E7 is probably related to the recruitment of survival pathways. In addition, because E6 suppressed apoptosis in
p53
knockout cells, our data also suggest that E6 may participate in a
p53
-independent process that protects cells from apoptosis.
...
PMID:Transformation by human papillomavirus 16 E6 and E7: role of the insulin-like growth factor 1 receptor. 889 68
Platelet-derived growth factor (PDGF) signals a diversity of cellular responses in vitro, including cell proliferation, survival, transformation, and chemotaxis. PDGF functions as a "competence factor" to induce a set of early response genes expressed in G1 including p21WAF1/CIP1, a functional mediator of the tumor suppressor gene
p53
in G1/S checkpoint. For PDGF-stimulated cells to progress beyond G1 and transit the cell cycle completely, progression factors in serum such as insulin and
IGF-1
are required. We have recently shown a novel role of PDGF in inducing apoptosis in growth-arrested murine fibroblasts. The PDGF-induced apoptosis is rescued by insulin, suggesting that G1/S checkpoint is a critical determinant for PDGF-induced apoptosis. Because recent studies suggest that radiation-induced signal transduction pathways interact with growth factor-mediated signaling pathways, we have investigated whether activation of the PDGF-signaling facilitates the radiation-induced apoptosis in the absence of functional
p53
. For this study we have used the 125-IL cell line, a mutant p53-containing, highly metastatic, and hormone-unresponsive human prostate carcinoma cell line. PDGF signaling is constitutively activated by transfection with a p28v-sis expression vector, which was previously shown to activate PDGF alpha- and beta- receptors. Although the basal level of p21WAF1/CIP1 expression and radiation-induced apoptosis were not detectable in control 125-IL cells as would be predicted in mutant p53-containing cells, activation of PDGF-signaling induced expression of p21WAF1/CIP1 and radiation-induced apoptosis. Our study suggests that the level of "competence" growth factors including PDGF may be one of the critical determinants for radiation-induced apoptosis, especially in cells with loss of
p53
function at the site of radiotherapy in vivo.
...
PMID:Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. 933 56
The loss or functional inactivation of tumor suppressor genes appears to be one of the most fundamental genetic mechanisms of tumorigenesis, and rational insights into the signaling pathways of tumor suppressor genes have emerged as a successful strategy of identifying novel drug discovery targets downstream of the tumor suppressor protein itself. Elucidation of novel pathways downstream of
p53
have established a link between this important tumor suppressor gene and the insulin-like growth factor-1 receptor (IGF-1r), either via direct regulation of
IGF-1
receptor levels, or modulation of IGFs via transactivation of the insulin-like growth factor-binding protein 3 (IGF-BP3) gene. Binding of IGF-BP3 to IGFs inhibits both their mitogenic and cell survival functions, highlighting a novel pathway whereby
p53
may regulate apoptosis in tumor cells.
...
PMID:The p53/IGF-1 receptor axis in the regulation of programmed cell death. 944 44
Insulin-like growth factor (IGF)-1 inhibits apoptosis, but its mechanism is unknown. Myocyte stretching activates
p53
and
p53
-dependent genes, leading to the formation of angiotensin II (Ang II) and apoptosis. Therefore, this in vitro system was used to determine whether
IGF-1
interfered with
p53
function and the local renin-angiotensin system (RAS), decreasing stretch-induced cell death. A single dose of 200 ng/ml
IGF-1
at the time of stretching decreased myocyte apoptosis 43% and 61% at 6 and 20 hours. Ang II concentration was reduced 52% at 20 hours. Additionally,
p53
DNA binding to angiotensinogen (Aogen), AT1 receptor, and Bax was markedly down-regulated by
IGF-1
via the induction of Mdm2 and the formation of Mdm2-
p53
complexes. Concurrently, the quantity of
p53
, Aogen, renin, AT1 receptor, and Bax was reduced in stretched myocytes exposed to
IGF-1
. Conversely, Bcl-2 and the Bcl-2-to-Bax protein ratio increased. The effects of
IGF-1
on cell death, Ang II synthesis, and Bax protein were the consequence of Mdm2-induced down-regulation of
p53
function. In conclusion, the anti-apoptotic impact of
IGF-1
on stretched myocytes was mediated by its capacity to depress
p53
transcriptional activity, which limited Ang II formation and attenuated the susceptibility of myocytes to trigger their endogenous cell death pathway.
...
PMID:Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. 1002 14
This review primarily discusses work that has been performed in our laboratories and that of our direct collaborators and therefore does not represent an exhaustive review of the current literature. Our aim is to further discuss the role that gene expression plays in neuronal plasticity and pathology. In the first part of this review we examine activity-dependent changes in the expression of inducible transcription factors (ITFs) and neurotrophins with long-term potentiation (LTP) and kindling. This work has identified particular ITFs (Krox-20 and Krox-24) and neurotrophin systems (particularly the brain-derived neurotrophic factor (BDNF)/tyrosine receptor kinase-B, Trk-B system) that may be involved in stabilizing long-lasting LTP (i.e. LTP3). We also show that changes in the expression of other ITFs (Fos, Jun-D and Krox-20) and the BDNF/trkB neurotrophin system may play a central role in the development of hippocampal kindling, an animal model of human temporal lobe epilepsy. In the next part of this review we examine changes in gene expression after neuronal injuries (ischemia, prolonged seizure activity and focal brain injury) and after nerve transection (axotomy). We identify apoptosis-related genes (
p53
, c-Jun, Bax) whose delayed expression selectively increases in degenerating neurons, further suggesting that some forms of neuronal death may involve apoptosis. Moreover, since overexpression of the tumour-suppressor gene
p53
induces apoptosis in a wide variety of dividing cell types we speculate that it may perform the same function in post-mitotic neurons following brain injuries. Additionally, we show that neuronal injury is associated with rapid, transient, activity-dependent expression of neurotrophins (BDNF and activinA) in neurons, contrasting with a delayed and more persistent injury-induced expression of certain growth factors (
IGF-1
and TGFbeta) in glia. In this section we also describe results linking ITFs and neurotrophic factor expression. Firstly, we show that while BDNF and trkB are induced as immediate-early genes following injury, the injury-induced expression of activinA and trkC may be regulated by ITFs. We also discuss whether loss of retrograde transport of neurotrophic factors such as nerve growth factor following nerve transection triggers the selective and prolonged expression of c-Jun in axotomized neurons and whether c-Jun is responsible for regeneration or degeneration of these axotomized neurons. In the last section we further examine the role that gene expression may play in memory formation, epileptogenesis and neuronal degeneration, lastly speculating whether the expression of various growth factors after brain injury represents an endogenous neuroprotective response of the brain to injury. Here we discuss our results which show that pharmacological enhancement of this response with exogenous application of
IGF-1
or TGF-beta reduces neuronal loss after brain injury.
...
PMID:Activity and injury-dependent expression of inducible transcription factors, growth factors and apoptosis-related genes within the central nervous system. 1008 Mar 84
Insulin-like growth factors (IGFs) regulate important cellular activities involving cell proliferation, differentiation, and apoptosis. Emerging evidence suggests that members of the IGF family, including
IGF-1
, IGF-2, the
IGF-1
receptor (IGF-1R), and the IGF binding proteins (IGFBPs), play important roles in the development and progression of cancer. Both in vitro and in vivo studies show that IGFs are strong mitogens for a variety of cancer cells.
IGF-1
also has an antiapoptotic action on cancer. IGF-1R, overexpressed in cancer cells, mediates the effects of IGFs and plays a role in cell transformation induced by tumor virus and oncogene products. IGFBPs inhibit the actions of IGFs and mediate the anti-proliferative effect of wild-type
p53 protein
, retinoic acid, vitamin D, and transforming growth factor-beta (TGF-beta). Findings from epidemiologic studies support the involvement of IGF in cancer etiology. Diet, nutrition, and other lifestyle features affect the expression and production of
IGF-1
and other members of the IGF family. This may provide new approaches for cancer prevention. Growth hormone (GH) stimulates the production of
IGF-1
. Use of GH replacement therapy to improve physiological and psychological well-being and to prevent aging-related diseases has been recommended. Given the close relationship between GH and
IGF-1
, the long-term safety of GH treatment warrants a serious concern.
...
PMID:Insulin-like growth factors and cancer. 1023 99
1
2
3
4
5
6
7
8
9
10
Next >>